#China #Beijing #Shineco #BICC #Dong'ao Health

Shineco (SISI) Accelerates Growth

Shineco Inc. (NASDAQ: SISI), renowned for its innovative work in induced pluripotent stem cell (iPSC) technology, is making significant strides with two remarkable announcements. On September 12, 2025, the company confirmed that its subsidiary, Xi'an Dong'ao Health Management Co., Ltd., has secured a technology services contract worth $8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. This contract is pivotal in guiding the research and development of microalgae-derived extracellular vesicles (EVs) technology, a burgeoning field with potential implications in health and wellness.

Contract Details and Objectives

The contract is scheduled to span from August 25, 2025, to December 31, 2026, with several strategic objectives outlined. The primary aim is to develop a robust R&D system from foundational research through to product development and market translation. Key tasks include validating functionality within the basic research phase, resolving bottlenecks in large-scale extraction processes, and developing at least two therapeutic products backed by regulatory support.

This initiative not only adds immediate financial momentum for Shineco, but the structured payment system associated with the contract ensures steady revenue flows as milestones are achieved. An initial payment of $560,000 has already been received, with the subsequent amounts contingent on progress in the R&D phases—an approach that is set to sustain long-term profitability and position Shineco favorably in competitive markets.

Strategic Collaboration with BICC

Alongside this promising contract, Shineco has also strengthened its international position by establishing a partnership with BICC, a leading biotechnology firm based in Singapore. A high-profile delegation from BICC, including key executives, recently visited Dong'ao Health to explore collaborative opportunities that benefit both entities.

The visit resulted in a consensus on establishing a joint laboratory, opening avenues for technological exchange, and integrating BICC's extensive network of over 3,000 agents distributed throughout Southeast Asia with Dong'ao Health's existing domestic channels. Plans to establish stem cell transfusion centers to enhance clinical services were also discussed. This partnership exemplifies Shineco's vision of merging technology development with ecosystem synergies, fostering enhanced opportunities for growth in domestic and international markets.

The Dual Approach to Growth

Shineco's strategy combines distinct yet complementary elements: the development of cutting-edge technologies and the establishment of a synergistic ecosystem. Leveraging the strengths of both Dong'ao Health and BICC allows for a robust market entry, not only improving immediate cash flows but also laying a foundation for sustainable profits. Dong'ao Health is positioned as a pioneer in the biocellular market, and this alignment with BICC could significantly boost Shineco’s capacity for scaling innovative solutions.

CEO Jennifer Zhan remarked on this dual approach, stating, "This contract validates our strategy to monetize pioneering research while simultaneously expanding into international markets. By combining our technological innovations with BICC's robust network, we are setting the stage for substantial growth going forward."

Future Prospects

With these developments, Shineco is positioned at the forefront of not just technological advancement but also strategic collaboration in the biotech industry. The company has indicated its commitment to provide updates on both the R&D contract execution and the fruitful collaboration with BICC in line with NASDAQ's disclosure requirements. Shineco Inc. remains dedicated to enhancing the quality of life through safe and effective health solutions driven by state-of-the-art technology.

For more insights on Shineco's technologies and developments, please visit Shineco's website.

About Shineco and Partners

Xi'an Dong'ao Health Management Co., Ltd. specializes in providing compliant biostorage and clinical applications tailored for health management protocols. BICC Pte Ltd. has emerged as an innovative force within the Southeast Asian biotech landscape, uniquely positioned with its network and patented technologies. Together, they are set to revolutionize the health and wellness market through their combined expertise and resources.